HCW11-040 / HCW Biologics - LARVOL DELTA

HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire) - "Results of these preclinical studies also highlight the advantages of HCW11-040 over the first generation immune checkpoint inhibitors: To improve efficacy, HCW11-040 is equipped with other moieties in addition to pembrolizumab which neutralizes the immunosuppressive cytokine, TGF-β, and activates effector immune cell responses; The mouse homologue of HCW11-040 expands progenitor exhausted T (TPEX) cells significantly better than mouse ICI or pembrolizumab alone. TPEX cells are a key subset of T cells that respond to ICIs. TPEX cells have self-renewal capabilities and are considered a primary driver for the success of ICI therapies, making them an attractive target for improving treatment outcomes; HCW11-040 expands and activates human peripheral blood lymphocytes (PBMCs) and memory T cells significantly better than pembrolizumab alone."

Preclinical • Leukemia • Pancreatic Cancer

A novel tetra-specific pembrolizumab-based immunotherapeutic (SITC 2025) - "HCW11-040 was also found to neutralize the immunosuppresiveness of TGF-β1. Extensive studies are being conducted to evaluate its anti-tumor activities in comparison with pembrolizumab in animal models.Conclusions HCW11-040 may serve as a novel therapeutic to simultaneously work as an immune checkpoint inhibitor, provide immunostimulation of immune cells and lessen immunosuppression associated with tumor microenvironment of cancer."

Oncology • Pancreatic Cancer • Solid Tumor • CD4 • CD8 • IL15 • IL7 • TGFB1 • TRB

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment (GlobeNewswire) - "Dr. Rhode’s presentation features the Company’s lead product candidate, known as HCW11-040, which is the Company’s franchise immunotherapeutic for internal clinical development as a second-generation immune checkpoint inhibitor....At the upcoming 40th annual meeting of the Society for Immunotherapy of Cancer ('SITC'), the Company will be presenting extensive data for HCW11-040 in a poster presentation..."

Preclinical • Oncology

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development (GlobeNewswire) - "In the presentation, Dr. Wong also highlighted the results of preclinical studies showing that HCW11-040 outperformed pembrolizumab monotherapy in immune-cell activation and expansion, enhancement of immune-cell infiltration into the tumors, and immune-cell cytotoxicity against cancer cells. In other preclinical models, the Company showed that HCW11-040 is not likely to overstimulate the immune system resulting in a cytokine storm when administered by subcutaneous injection using the Company’s projected efficacious dose levels."

Preclinical • Oncology